Colorectal Cancer Research Findings
Home » Guardant360® » Colorectal Cancer Research Findings

Findings from HERACLES A Study

For patients with metastatic colorectal cancer (mCRC), the HERACLES A Study showed that, Guardant360® can detect actionable mutations that can result in selection of targeted therapy and may lead to better patient outcomes1.

Guardant360® showed a correlation between clinical outcomes and adjusted ERBB2 copy number. ERBB2 (HER2) amplification is a recommended biomarker in mCRC.

BOR* in baseline plasma ERBB2 positive metastatic CRC1

PFS by ERBB2 adjusted plasma copy number (pCN)1

97.9% sensitivity for

Siravegna G, Sartore-Bianchi A, Nagy RJ et al. Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clin Cancer Res. 2019 May 15;25(10):3046-3053. doi: 10.1158/1078-0432.CCR-18-3389.

Message us